Ashby H, DiMattina M, Linehan W M, Robertson C N, Queenan J T, Albertson B D
Department of Obstetrics and Gynecology, Georgetown University Medical Center, Washington, D.C. 20007.
J Clin Endocrinol Metab. 1989 Feb;68(2):505-8. doi: 10.1210/jcem-68-2-505.
Suramin has recently been used to treat patients with acquired immune deficiency syndrome because of the action of this drug on reverse transcriptase. Patients so treated developed the symptoms and hormonal profiles of adrenal insufficiency. To evaluate the mechanism of action of suramin on adrenalcortical function, adrenal mitochondrial and microsomal preparations from five subjects were assayed for steroidogenic enzyme activity in the presence and absence of suramin. Specifically, 3 beta-hydroxysteroid dehydrogenase/isomerase, 17 alpha-hydroxylase, 21-hydroxylase, 11 beta-hydroxylase, and 17,20-desmolase activities were measured in the presence of 0-5000 mumol/L suramin concentrations. In all assays, enzyme activities decreased in a dose-dependent fashion as suramin concentrations increased. The drug doses (calculated) that caused 50% inhibition of enzyme activity were: 21-hydroxylase activity, 50 mumol/L; 17 alpha-hydroxylase activity, 25 mumol/L; 17,20-desmolase activity, 50 mumol/L; 11 beta-hydroxylase, 2 mumol/L, and 3 beta-hydroxysteroid dehydrogenase/isomerase, 1200 mumol/L. These results suggest that suramin has a concentration-dependent inhibitory effect on the key P-450-regulated enzymatic steps in adrenal glucocorticoid steroidogenesis, which may explain the development of adrenal insufficiency in acquired immune deficiency syndrome patients treated with suramin.
苏拉明最近被用于治疗获得性免疫缺陷综合征患者,因为该药物对逆转录酶有作用。接受如此治疗的患者出现了肾上腺功能不全的症状和激素谱。为了评估苏拉明对肾上腺皮质功能的作用机制,对五名受试者的肾上腺线粒体和微粒体制剂在有和没有苏拉明的情况下进行了类固醇生成酶活性测定。具体而言,在0至5000 μmol/L的苏拉明浓度下测量了3β-羟基类固醇脱氢酶/异构酶、17α-羟化酶、21-羟化酶、11β-羟化酶和17,20-裂解酶的活性。在所有测定中,随着苏拉明浓度的增加,酶活性呈剂量依赖性下降。导致酶活性50%抑制的药物剂量(计算值)为:21-羟化酶活性,50 μmol/L;17α-羟化酶活性,25 μmol/L;17,20-裂解酶活性,50 μmol/L;11β-羟化酶,2 μmol/L,以及3β-羟基类固醇脱氢酶/异构酶,1200 μmol/L。这些结果表明,苏拉明对肾上腺糖皮质激素类固醇生成中关键的P-450调节酶步骤具有浓度依赖性抑制作用,这可能解释了用苏拉明治疗的获得性免疫缺陷综合征患者肾上腺功能不全的发生。